In a significant milestone for artificial intelligence-driven medicine, Alphabet’s Isomorphic Labs is preparing to initiate human clinical trials for its first generation of AI-designed therapeutics. The London-based subsidiary, spun out from Google DeepMind in 2021, is staffing up final teams and expects to begin testing its computational compounds in human subjects imminently, according to company president Colin Murdoch. This development marks a critical validation point for AI’s role in revolutionizing one of science’s most complex and costly endeavors.
The company recently secured $600 million in its first external funding round led by Thrive Capital, with participation from GV (formerly Google Ventures) and additional backing from Alphabet. This substantial investment, finalized in April 2025, will accelerate Isomorphic’s expansion into biologics and boost computational resources for its drug design engine. The financing follows major research collaborations with pharmaceutical giants Novartis and Eli Lilly, partnerships that could yield nearly $3 billion for Isomorphic through upfront payments, milestones, and future royalties.
AlphaFold’s Evolution From Protein Prediction to Drug Design
Isomorphic’s foundation rests on DeepMind’s AlphaFold breakthrough, an AI system that solved the 50-year “protein folding problem” by accurately predicting protein structures from amino acid sequences. The technology’s progression from predicting individual proteins (AlphaFold2) to modeling complex molecular interactions (AlphaFold3) established its drug discovery utility. AlphaFold3, released to the scientific community for non-commercial use in 2024, can predict structures and interactions across DNA, RNA, ligands, and other biological components essential for therapeutic development.
“This was the inspiration for Isomorphic Labs,” Murdoch told Fortune. “AlphaFold demonstrated we could do something very foundational in AI that could help unlock drug discovery”. The company now employs over 200 interdisciplinary experts blending machine learning specialists with pharmaceutical veterans who actively design cancer drugs in collaboration with AI systems at their King’s Cross headquarters.
Redefining Pharma Economics Through Computational Precision
Isomorphic’s approach confronts pharmaceutical development’s stark realities: traditional drug discovery often requires 10-15 years and over $2 billion per approved therapy, with approximately 90% failure rates once human trials commence. The company aims to invert this equation through what Murdoch describes as a “world-class drug design engine,” combining predictive accuracy with the generation of molecules.
While supporting partner programs, Isomorphic simultaneously advances internal drug candidates in oncology and immunology. These proprietary compounds will undergo early-stage human testing before potential out-licensing. “We identify an unmet need, start our drug design programs, develop those, and put them into human clinical trials,” Murdoch explained, noting they are “making good progress” toward this milestone.
Industry-Wide Transformation and Validation Challenges
Isomorphic’s progress occurs alongside broader AI drug discovery advances. Insilico Medicine recently entered phase 2 trials with an entirely AI-designed pulmonary fibrosis drug, while companies like Recursion Pharmaceuticals and Verge Genomics deploy comprehensive computational platforms integrating multi-modal biological data. Still, skepticism persists regarding AI’s clinical translatability. Aaron Smith, founder of AI clinical trial firm Unlearn, notes that pharmaceutical adoption faces hurdles including “communication gaps,” “trust issues,” and “knowledge gaps” about AI’s capabilities and limitations.
Isomorphic confronts these challenges through rigorous validation. “The next big milestone is going out to clinical trials, starting to put these things into human beings,” Murdoch stated, emphasizing their goal to reach “100% conviction that drugs we’re developing will work in human trials”. The company’s ambition extends beyond incremental improvements to a fundamental reimagining of therapeutic creation. Murdoch envisions a future where researchers could theoretically input a disease profile and have an AI-designed treatment emerge at “the click of a button”.
The Road to Radical Efficiency
As Isomorphic prepares its clinical transition, its work exemplifies AI’s potential to reshape therapeutic development timelines and economics. If successful, the approach could compress discovery phases that traditionally take years into months while substantially reducing costs. Vince Hankes, Thrive Capital partner, cites Isomorphic CEO Demis Hassabis’s “extraordinarily special” leadership and the team’s “cutting-edge research talent” as pivotal advantages.
The imminent human trials represent more than a company milestone; they are a critical test for AI’s capacity to address biology’s complexity. Success could accelerate investment across computational biology, while setbacks might reinforce traditional pharmaceutical workflows. Either outcome will provide unprecedented data on whether artificial intelligence can truly deliver what Murdoch and Hassabis envision: a future where disease itself becomes solvable.
Subscribe to my whatsapp channel
Comments are closed.